<div id="readability-page-1"><p>Osaic Holdings Inc. cut its holdings in shares of  TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 113,345 shares of the biopharmaceutical company's stock after selling 39,445 shares during the period. Osaic Holdings Inc. owned approximately 0.07% of TG Therapeutics worth $4,079,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>TG Therapeutics</strong> alerts:</span></p></div><ul><li>The Most Shorted Stocks in June: Hold, Short, or Squeeze?</li></ul><p>Other large investors have also added to or reduced their stakes in the company. Ameritas Advisory Services LLC bought a new position in  TG Therapeutics in the second quarter worth approximately $25,000.  Johnson Financial Group Inc. purchased a new position in  TG Therapeutics during the second quarter valued at $25,000.  SVB Wealth LLC purchased a new stake in shares of  TG Therapeutics during the 1st quarter valued at about $37,000.  Private Wealth Asset Management LLC bought a new stake in shares of  TG Therapeutics in the 2nd quarter valued at approximately $37,000.  Finally, EverSource Wealth Advisors LLC lifted its position in  TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 573 shares during the last quarter. Institutional investors own  58.58% of the company's stock. </p><h2>TG Therapeutics Price Performance</h2><p>NASDAQ TGTX opened at $31.07 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The company has a market cap of $4.93 billion, a PE ratio of 11.18 and a beta of 2.01. The firm's 50 day moving average price is $32.23 and its 200-day moving average price is $33.34. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $46.48. </p><ul><li>TG Therapeutics Stock 300% Rally Has Legs Yet</li></ul><p>TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. During the same period in the previous year, the company posted $0.02 earnings per share. The firm's revenue was up 92.7% on a year-over-year basis.  Sell-side analysts forecast that  TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the business's stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the sale, the director owned 223,816 shares of the company's stock, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Corporate insiders own  10.64% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>Several brokerages have commented on TGTX. HC Wainwright assumed coverage on TG Therapeutics in a research report on Monday, October 6th. They issued a &#34;buy&#34; rating and a $60.00 price objective on the stock. Wall Street Zen raised shares of TG Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Sunday, December 14th. Weiss Ratings  restated a &#34;hold (c+)&#34; rating on shares of TG Therapeutics in a research note on Monday. B. Riley raised shares of TG Therapeutics to a &#34;strong-buy&#34; rating in a research report on Tuesday, November 4th. Finally, JPMorgan Chase &amp; Co. lifted their price target on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, November 3rd. One research analyst  has rated the stock with a Strong Buy rating, two have issued  a Buy rating and two have issued  a Hold rating to the company's stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $50.25.</p><p><b>Check Out Our Latest Research Report on TGTX</b></p><h2>TG Therapeutics Profile</h2> (Free Report)<p>TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.  </p><p>In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than TG Therapeutics</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><strong>Want to see what other hedge funds are holding TGTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in TG Therapeutics Right Now?</h2><p>Before you consider TG Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.</p><p>While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TGTX

<p>Osaic Holdings Inc. reduced its stake in TG Therapeutics by 25.8% in Q2, selling 39,445 shares. TG Therapeutics' stock opened at $31.07, with a market cap of $4.93 billion. Analysts forecast a moderate buy rating with a price target of $50.25. The company reported strong earnings, with a net margin of 84.13% and revenue up 92.7% year-over-year.</p>

Osaic Holdings Inc. Sells 39,445 Shares of TG Therapeutics, Inc. $TGTX